Compare GSK plc (GSK) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Schwab US Large Cap Growth ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Schwab US Large Cap Growth ETF trades at $36.74 (market cap $65.01B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays a 3.9% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| GSK | SCHG | |
|---|---|---|
Market Cap | $91.88B | $65.01B |
Volume | 7,730,529 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $61.18 | $36.93 |
52-Week Low | $43.24 | $28.10 |
Typical Hold Time | 93 Days | 50 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
SCHG (Schwab U.S. Large-Cap Growth ETF) trades at $36.42, down 1.22% with a bullish technical signal from moving averages. The ETF focuses on large-cap growth stocks with heavy concentration in top holdings like Apple. Recent news highlights SCHG's long-term growth potential and tax-efficient characteristics for retirement planning.
SCHG offers exposure to quality growth companies at a low 0.03% expense ratio, but faces concentration risk in top holdings. The ETF's performance depends heavily on megacap tech stocks, making it vulnerable to sector rotations. Long-term growth prospects remain strong based on historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
